SOURCE: Wall Street Equity Research

Wall Street Equity Research

September 22, 2010 08:58 ET

Professional Research on Eli Lilly & Co. and Bristol-Myers Squibb - Overview of the Major Drug Makers Industry

JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 22, 2010) - allows shareholders to gain full understanding of the economic and market forces influencing the major drug manufacturers industry, and offers free research on industry players Eli Lilly & Co. (NYSE: LLY) and Bristol-Myers Squibb Co. (NYSE: BMY). Register today at to receive free research reports on these companies.

The Drug Manufacturing sector faces some interesting challenges currently. One major challenge involves governments in the European Union controlling drug prices for their national health programs. Nearly all of the countries have fixed prices lower in an attempt to shore up their budget concerns. Also, European governments are requiring that drug manufacturers provide more proof of safety and effectiveness for the drugs before the governments buy them. is a specialized website where investors can have complete access to free reports on major drug manufacturers industry; traders looking for analyst opinions on Eli Lilly & Co., Bristol-Myers Squibb Co. and other players in the industry are welcomed to sign up for a free one year membership at

Another issue facing the sector is the current legal battle of controversial "pay-for-delay" settlements. While a judge recently ruled that the practice of brand named drug makers paying generic companies to defer introduction of generic drugs was legal, the case could make it to the U.S. Supreme court because of its national importance. Brand name drug prices typically fall 80% when generics are introduced. The Federal Trade Commission argues that this practice is anti-competitive and costs consumers billions of dollars every year. Visit us at to understand the catalysts and forces driving or affecting major drug manufacturers stocks.

Elsewhere, companies are looking to mergers and acquisitions to help support growth in the face of huge patent fall-off during the next few years. Companies within the sector with weak pipelines are buying up smaller manufactures and biotech companies. One of the most promising companies with strong pipeline is Bristol-Myers Squibb Co. which has a potential of 5 drugs due to be launched by 2010 as opposed to Eli Lilly & Co. which is struggling in light of losing patent protections for a number of its best selling drugs. Shareholders and investors can sign up today at or to download the full reports on Eli Lilly & Co. and Bristol-Myers Squibb Co.

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information